https://explicyte.kipdev-s2.com/publication/how-tumor-derived-gaba-disables-tumor-tlss-and-drives-anti-pd-1-resistance-in-cancer/ 2026-07-27T15:25:04+00:00 https://explicyte.kipdev-s2.com/publication/how-a-cd52%e2%81%ba-myeloid-subset-drives-mesenchymal-breast-cancer-stemness-through-membrane-bound-tgf-%ce%b21/ 2026-07-27T15:10:53+00:00 https://explicyte.kipdev-s2.com/publication/how-tertiary-lymphoid-structures-predict-immunotherapy-response-and-how-to-induce-them-in-cold-tumors/ 2026-07-27T14:54:34+00:00 https://explicyte.kipdev-s2.com/publication/why-the-most-metabolically-active-soft-tissue-sarcomas-are-also-the-most-immune-infiltrated-and-what-that-means-for-immunotherapy-selection/ 2026-07-27T14:18:07+00:00 https://explicyte.kipdev-s2.com/publication/dual-ido1-tdo2-inhibition-amplifies-temozolomide-in-glioblastoma-and-flips-the-cd8-treg-balance/ 2026-07-27T14:05:50+00:00 https://explicyte.kipdev-s2.com/publication/why-cd8-t-cell-exhaustion-predicts-immunotherapy-resistance-in-lung-cancer-and-a-25-gene-signature-that-flags-it/ 2026-07-27T13:49:35+00:00 https://explicyte.kipdev-s2.com/publication/how-trop2-predicts-resistance-to-immune-checkpoint-inhibitors-in-advanced-lung-cancer-and-who-might-benefit-from-combinations/ 2026-07-27T13:36:23+00:00 https://explicyte.kipdev-s2.com/publication/why-immune-inflamed-pleomorphic-sarcomas-respond-poorly-to-neoadjuvant-chemotherapy-and-how-to-stratify-patients-before-surgery/ 2026-07-27T13:27:49+00:00 https://explicyte.kipdev-s2.com/publication/why-advanced-gastric-cancers-resist-pd-1-plus-anti-angiogenic-therapy-and-how-m2-macrophages-mark-the-non-responders/ 2026-07-27T13:07:45+00:00 https://explicyte.kipdev-s2.com/publication/does-metronomic-trabectedin-reprogram-the-sarcoma-immune-microenvironment-a-macrophage-and-t-cell-shift-that-tracks-with-better-outcomes/ 2026-07-24T16:35:46+00:00 https://explicyte.kipdev-s2.com/publication/can-an-oncolytic-virus-turn-cold-sarcomas-hot-intratumoral-jx-594-with-avelumab-raised-cd8-t-cells-but-not-responses/ 2026-07-24T16:26:26+00:00 https://explicyte.kipdev-s2.com/publication/can-a-single-gut-bacterium-rescue-failing-immunotherapy-f-prausnitzii-strain-exl01-restores-checkpoint-inhibitor-response/ 2026-07-24T16:18:07+00:00 https://explicyte.kipdev-s2.com/publication/can-blocking-prmt5-starve-sarcomas-of-energy-inhibiting-the-enzyme-shuts-down-tumor-glycolysis-and-growth/ 2026-07-24T15:51:22+00:00 https://explicyte.kipdev-s2.com/publication/why-ido1-in-inflamed-tls-positive-lung-tumors-predicts-immunotherapy-response-and-marks-who-might-benefit-from-ido1-inhibitors/ 2026-07-24T15:03:47+00:00 https://explicyte.kipdev-s2.com/publication/how-to-screen-for-mature-tertiary-lymphoid-structures-in-routine-pathology-a-standardized-method-validated-across-357-tumors/ 2026-07-24T14:42:34+00:00 https://explicyte.kipdev-s2.com/publication/can-a-simple-blood-test-predict-who-responds-to-immunotherapy-circulating-l-arginine-tracks-checkpoint-inhibitor-survival/ 2026-07-24T14:28:25+00:00 https://explicyte.kipdev-s2.com/publication/does-acetaminophen-blunt-cancer-immunotherapy-plasma-evidence-links-paracetamol-to-worse-checkpoint-inhibitor-outcomes/ 2026-07-24T14:28:21+00:00 https://explicyte.kipdev-s2.com/publication/why-intravenous-oncolytic-virus-jx-594-lit-up-immune-biomarkers-but-not-tumor-responses-in-hr-breast-cancer/ 2026-07-24T13:57:56+00:00 https://explicyte.kipdev-s2.com/publication/how-tolerogenic-cdc1-dendritic-cells-educate-inflammatory-cdc2-by-exporting-the-tryptophan-metabolite-l-kynurenine/ 2026-07-24T13:39:13+00:00 https://explicyte.kipdev-s2.com/publication/why-ido1-inhibitors-failed-in-the-clinic-and-whats-next-for-targeting-tryptophan-metabolism-in-cancer/ 2026-07-24T13:37:21+00:00 https://explicyte.kipdev-s2.com/publication/how-tertiary-lymphoid-structures-predict-pembrolizumab-response-in-soft-tissue-sarcoma-and-why-plasma-cells-matter/ 2026-07-24T13:05:22+00:00 https://explicyte.kipdev-s2.com/publication/why-the-tlr4-agonist-g100-boosted-t-cells-but-not-pd-1-response-in-cold-soft-tissue-sarcoma/ 2026-07-24T13:04:38+00:00 https://explicyte.kipdev-s2.com/publication/why-systemic-oncolytic-virus-jx-594-stirred-an-immune-signal-but-not-clinical-benefit-in-soft-tissue-sarcoma/ 2026-07-24T13:02:57+00:00 https://explicyte.kipdev-s2.com/publication/how-fucoidan-activates-immune-cells-and-independently-stalls-prostate-cancer-growth-alongside-nivolumab/ 2026-07-24T11:04:20+00:00 https://explicyte.kipdev-s2.com/publication/how-cd95-keeps-nf-%ce%bab-switched-off-in-triple-negative-breast-cancer-and-what-its-loss-unleashes/ 2026-07-24T10:51:31+00:00 https://explicyte.kipdev-s2.com/publication/how-adora2b-drives-metastasis-in-pleomorphic-sarcoma-and-why-its-a-tractable-target/ 2026-07-24T10:06:23+00:00 https://explicyte.kipdev-s2.com/publication/how-normal-appearing-vitiligo-skin-keeps-its-pigment-pd-1-and-regulatory-t-cells-restrain-disease-ready-cd8-t-cells/ 2026-07-24T10:05:18+00:00 https://explicyte.kipdev-s2.com/publication/how-an-engineered-cd40-antibody-injected-into-tumors-builds-the-immune-structures-that-drive-whole-body-cancer-responses/ 2026-07-24T10:04:40+00:00 https://explicyte.kipdev-s2.com/publication/how-regorafenib-plus-avelumab-reshapes-the-immune-microenvironment-of-cold-soft-tissue-sarcomas-and-why-response-stays-elusive/ 2026-07-24T09:48:23+00:00 https://explicyte.kipdev-s2.com/publication/regorafenib-plus-avelumab-in-advanced-neuroendocrine-tumors-and-the-ido1-biomarker-that-predicts-resistance/ 2026-07-24T09:46:50+00:00 https://explicyte.kipdev-s2.com/publication/why-do-some-mature-tls-lung-cancers-resist-immunotherapy-two-caf-subsets-that-drive-primary-resistance-in-nsclc/ 2026-07-24T09:45:45+00:00 https://explicyte.kipdev-s2.com/publication/why-intratumoral-cd163-macrophages-predict-anti-pd-1-resistance-in-non-small-cell-lung-cancer/ 2026-07-24T09:44:47+00:00 https://explicyte.kipdev-s2.com/publication/which-biliary-tract-cancers-benefit-from-regorafenib-avelumab-and-which-biomarkers-matter/ 2026-07-24T09:43:14+00:00 https://explicyte.kipdev-s2.com/publication/can-trabectedin-plus-durvalumab-help-platinum-resistant-ovarian-carcinoma-and-soft-tissue-sarcoma/ 2026-07-24T09:42:38+00:00 https://explicyte.kipdev-s2.com/publication/how-cd95-fas-helps-triple-negative-breast-cancer-escape-nk-cell-control-in-preclinical-models/ 2026-07-24T09:41:46+00:00 https://explicyte.kipdev-s2.com/publication/how-plasma-lif-predicts-immune-checkpoint-blockade-resistance-and-a-tls-poor-tumor-microenvironment/ 2026-07-24T09:40:36+00:00 https://explicyte.kipdev-s2.com/publication/how-mature-tlss-identify-solid-tumor-patients-more-likely-to-benefit-from-pd-1-blockade/ 2026-07-24T09:39:30+00:00 https://explicyte.kipdev-s2.com/publication/can-cd163-macrophages-help-select-mss-colorectal-cancer-patients-for-regorafenib-plus-avelumab/ 2026-07-24T09:38:32+00:00 https://explicyte.kipdev-s2.com/publication/why-ido1-blockade-lowered-kynurenine-but-failed-to-improve-anti-pdl1-efficacy-in-sarcoma/ 2026-07-24T09:37:11+00:00 https://explicyte.kipdev-s2.com/publication/does-cabozantinib-help-in-advanced-ewing-sarcoma-and-osteosarcoma-and-can-plasma-biomarkers-flag-who-responds/ 2026-07-24T09:36:12+00:00 https://explicyte.kipdev-s2.com/publication/why-melanoma-escapes-braf-inhibitors-the-ahr-transcription-factor-behind-resistance-and-relapse/ 2026-07-24T09:35:35+00:00 https://explicyte.kipdev-s2.com/publication/why-pd-1-blockade-falls-short-in-soft-tissue-sarcoma-and-the-macrophage-ido1-axis-behind-it/ 2026-07-24T09:34:21+00:00 https://explicyte.kipdev-s2.com/publication/how-baf-pbaf-chromatin-remodeler-mutations-predict-better-checkpoint-inhibitor-outcomes-and-point-toward-combination-strategies/ 2026-07-24T09:32:49+00:00 https://explicyte.kipdev-s2.com/publication/why-ido1-inhibitors-fell-short-in-cancer-immunotherapy-and-what-comes-next-for-tryptophan-targeting/ 2026-07-10T09:42:07+00:00 https://explicyte.kipdev-s2.com/publication/why-ido1-staining-can-miss-l-kynurenine-production-in-colorectal-and-breast-tumors/ 2026-07-09T09:45:09+00:00